A highly sensitive and selective viral protein detection method based on RNA oligonucleotide nanoparticle by Roh, Changhyun et al.
© 2010 Roh et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2010:5 323–329
International Journal of Nanomedicine
O R I G I N A L   R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
323
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
A highly sensitive and selective viral protein 
detection method based on RNA  
oligonucleotide nanoparticle
Changhyun Roh1 
Ho-Young Lee2 
Sang-Eun Kim2 
Sung-Kee Jo1
1Radiation Research Division for 
Biotechnology, Advanced Radiation 
Technology Institute (ARTI), Korea 
Atomic Energy Research Institute 
(KAERI), Sinjeong-dong, Jeongeup, 
Jeonbuk, South Korea; 2Department 
of Nuclear Medicine, College of 
Medicine, Seoul National University, 
South Korea
Correspondence: Changhyun Roh 
Radiation Research Division for 
Biotechnology, Advanced Radiation 
Technology Institute (ARTI), Korea 
Atomic Energy Research Institute 
(KAERI), 1266, Sinjeong-dong, Jeongeup, 
Jeonbuk 580-185, South Korea 
Tel +82 63 570 3227 
Fax +82 63 570 3229 
Email chroh@kaeri.re.kr 
Sung-Kee Jo 
Radiation Research Division for  
Biotechnology, Advanced Radiation 
Technology Institute (ARTI), Korea 
Atomic Energy Research Institute 
(KAERI), 1266, Sinjeong-dong, Jeongeup, 
Jeonbuk 580-185, South Korea 
Tel +82 63 570 3200 
Fax +82 63 570 3229 
Email skjo@kaeri.re.kr
Abstract: Globally, approximately 170 million people (representing approximately 3% of the 
population worldwide), are infected with hepatitis C virus (HCV) and at risk of serious liver 
disease, including chronic hepatitis. We propose a new quantum dots (QDs)-supported RNA 
oligonucleotide approach for the specific and sensitive detection of viral protein using a biochip. 
This method was developed by immobilizing a HCV nonstructural protein 5B (NS5B) on the 
surface of a glass chip via the formation of a covalent bond between an amine protein group 
and a ProLinkerTM glass chip. The QDs-supported RNA oligonucleotide was conjugated via an 
amide formation reaction from coupling of a 5′-end-amine-modified RNA oligonucleotide on 
the surface of QDs displaying carboxyl groups via standard EDC coupling. The QDs-conjugated 
RNA oligonucleotide was interacted to immobilized viral protein NS5B on the biochip. The 
detection is based on the variation of signal of QDs-supported RNA oligonucleotide bound on 
an immobilized biochip. It was demonstrated that the value of the signal has a linear relationship 
with concentrations of the HCV NS5B viral protein in the 1 µg mL-1 to 1 ng mL-1 range with a 
detection limit of 1 ng mL-1. The major advantages of this RNA-oligonucleotide nanoparticle 
assay are its good specificity, ease of performance, and ability to perform one-spot monitoring. 
The proposed method could be used as a general method of HCV detection and is expected to 
be applicable to other types of diseases as well.
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Introduction
Hepatitis C virus (HCV) is a major human health problem worldwide which can result 
in acute and chronic hepatitis, cirrhosis, and/or development of hepatocellular carci-
noma.1,2 HCV is a single-stranded positive sense RNA virus, the 9.6 kb genome of which 
is organized to contain a single, large translational open-reading frame that encodes a 
large polyprotein precursor (3010–3030 amino acids).3,4 The genome is replicated via 
a negative-stranded intermediate by the nonstructural protein 5B (NS5B), that is viral 
RNA-dependent RNA polymerase, a crucial and unique component of viral replication 
machinery.5–15 Because of its essential role in viral replication, HCV NS5B viral protein 
is regarded as a prime target for antiviral therapy.
There has been considerable interest in the development of simple and reliable 
methods for detection of HCV for applications in diagnostic medicine. Presently, 
the most widely used method for diagnosing HCV is the detection of anti-HCV 
antibodies using a screening enzyme-linked immunosorbent assay (ELISA), based 
on recombinant proteins from the genome of HCV.16,17 Although it is highly specific, 
this assay has limitations. For example, it cannot detect viruses during the early stage International Journal of Nanomedicine 2010:5 324
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of infection, at a time when antibodies against HCV antigens 
are not yet produced. The ELISA method sometimes gener-
ates false-positive or false-negative results.18 In addition, 
antibody use is temperature-sensitive, has specific reaction 
conditions, and requires a secondary antibody conjugated 
with enzyme and fluorescent dyes.
Quantum dots (QDs), which are colloidal nanoparticles 
of semiconductor materials with a CdSe/ZnS core shell, have 
attracted considerable attention in the fields of nanotechnol-
ogy and biotechnology, especially influorescence-based 
biological imaging applications.19–23 Semiconductor QDs 
possess remarkable optical characteristics compared with 
conventional organic fluorophores in terms of being bright, 
tunable, and having narrow fluorescence emission, as well 
as broad absorption spectra.24–26
Recently, there have been many studies on the devel-
opment of fluorescence-based assays for HCV RNA 
detection.27,28 Furthermore, a variety of assay methods have 
been developed for the qualitative and quantitative detec-
tion of HCV. Among the developed methods, biosensors 
based on RNA-oligonucleotide nanoparticles have attracted 
significant attention and are a promising method for specific 
detection of oligonucleotide because of their high sensitiv-
ity, low cost, rapid response, portability (compatibility 
for miniaturization), and low labor requirement. Several 
papers have been published on RNA biosensors for HCV 
detection,29,30 however, to date, little has been reported on 
HCV viral protein detection using QDs-supported RNA 
oligonucleotide. Driven by the need to detect the presence 
of the HCV disease, herein it was demonstrated for the 
first time that RNA oligonucleotide with functional signal 
sequence could be used for screening and quantifying HCV 
viral protein with selectivity and sensitivity. It is shown 
here that QDs-conjugated RNA oligonucleotide could be 
used as a probe for the detection of HCV viral protein using 
biochip.
Materials and methods
Materials
EDC (N-(3-dimethylaminopropyl)-N’  ethylcarbodiimide 
hydrochloride),  bovine  serum  albumin  (BSA)  and 
kanamycin were purchased from Sigma-Aldrich Chemi-
cal Co. (St. Louis, MO). Quantum dots (QDs) was pur-
chased from Invitrogen Corporation (Carlsbad, CA). The 
  ProlinkerTM-terminated glass slide was purchased from 
Proteogen (Seoul, Republic of Korea). All other chemicals 
were of the highest grade.
Conjugation of quantum dots  
and RNA oligonucleotide
An amine group with a terminal modification of NS5B RNA 
oligonucleotide (NS5Bnor) and NS5B RNA oligonucleotide 
mutant (NS5Bmut) were synthesized by BIONEER 
Co. Ltd. (Seoul, Republic of Korea) and carboxyl-
terminated QDs525 was purchased from Invitrogen (Cals-
bad, CA). The amino group of NS5B RNA oligonucleotide 
(NS5Bnor: H2N-5′-GGCCACAUUGUGAGGGGCUC-3′) 
and unspecific oligonucleotide (NS5Bmut: H2N-5′-
CCCCACAUUCUCACCCCCUC-3′) used as a mutant of 
NS5B RNA oligonucleotide were first covalently conjugated 
onto the surface of the carboxyl-terminated QDs (10 pM, 
1.25 µL). That is, 10 pM of QDs were conjugated with 400 pM 
of oligonucleotide with EDC 40 nM, 1 µL to activate amide 
bond formation to produce QDs-conjugated oligonucleotide 
(QDs-NS5B oligonucleotide) at a QDs:RNA oligonucleotide 
molar ratio of 1:40 for one hour at room temperature. There-
after, QDs-oligonucleotide conjugate was collected using a 
centrifugal filtration at 15,000 rpm for 30 minutes, followed 
by several washing steps with a Tris buffer (50 mM Tris-HCl 
pH 7.4, 5 mM KCl, 100 mM NaCl, 1 mM MgCl2, and 0.1% 
NaN3). After centrifugal filtration and washing, the pellet of 
QDs-conjugated RNA oligonucleotide was dispersed by brief 
sonication (22 kHz, amplitude 12 µm, and sonication time 
120 seconds) using a sonic dismembrator (Model F60 Sonic 
Dismembrator; Fisher Scientific, Fair Lawn, NJ).
Subcloning, expression,  
and purification of viral protein
The gene was amplified by a PCR with the primer set, 
sense: 5′-CGCGAATTCATGTCCTACACATGGACAGG-
3′; antisense: 5′-TTTCTCGAGTCGGTTGGGGAGCAG-
GTA-3′, containing restriction enzyme sites of EcoRI/XhoI. 
PCR was run with the following conditions on a thermal 
cycler: denaturation at 94° for one minute, annealing at 62° 
for 30 seconds, and extension at 72° for 2.5 minutes. The 
sequence was repeated 35 times followed by a seven-minute 
final extension step at 72°. The PCR product was digested 
with EcoRI/XhoI, and then ligated into a EcoRI/XhoI digested 
expression vector pET 28a+ (Novagen, Madison, WI), and 
transformed into Escherichia coli DH5α (Stratagene, La 
Jolla, CA). The correct colony transformed with an insert 
gene, and was then transformed into E. coli BL21 (DE3) 
(Stratagene, La Jolla, CA) and plated on Luria-Bertani (LB) 
agar containing 50 µg mL-1 kanamycin. The transformant 
was grown in a 250 mL flask containing 50 mL LB medium International Journal of Nanomedicine 2010:5 325
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supplemented with 50 µg mL-1 of kanamycin at 37° until 
the cell concentration reached an OD600 nm of 0.6, and 
  isopropyl-thio-β-D-galactopyranoside (IPTG) at a final 
concentration of 0.1 mM, followed by overnight growth 
at 25°C with shaking at 180 rpm. Cells were harvested by 
centrifugation at 4000 rpm for 30 minutes at 4°C and resus-
pended in 100 mM potassium phosphate buffer (pH 7.5) 
containing 1 mM phenylmethylsulfonyl fluoride (PMSF). 
Cells were lysed by sonic dismembrator. The cell debris was 
removed by centrifugation at 15,000 rpm for 30 minutes. The 
supernatant was collected and the recombinant protein was 
purified using a Ni-nitrilotriacetic acid (Ni-NTA) affinity 
chromatography column (Qiagen, Hilden, Germany). The 
supernatant was equilibrated with buffer A (10 mM Tri-HCl, 
500 mM NaCl, 5 mM imidazole, pH 8.0). The bound protein 
was eluted with buffer B (10 mM Tris-HCl, 500 mM NaCl, 
500 mM imidazole, pH 8.0) at 4°. Purity of the protein was 
estimated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in the eluted fractions, using 
10% polyacrylamide running gels.31 The purity of the enzyme 
was estimated by SDS-PAGE. The protein concentration 
was determined as described by Bradford32 with a BSA as 
standard. Enzyme samples were supplemented with 50% 
glycerol and stored at -20°C until use.
Electron microscopy
The free QDs and QD-conjugated RNA oligonucleotide were 
dried on a carbon Formvar-coated 200-mesh nickel grid, and 
were analyzed by transmission electron microscopy (TEM) 
(JEM-1400, JEOL Tokyo, Japan). The analysis of TEM was 
done at 80 kV.
Fluorescence microscopy
The recombinant HCV viral protein was immobilized 
directly onto the functional ProLinker-terminated surface. 
For the targeting of the specific RNA oligonucleotide, the 
QDs-conjugated RNA oligonucleotide was facilitated by 
spotting on immobilized HCV viral protein glass chip. After 
incubation for one hour at 25°C, the glass chip was then 
washed three times with the phosphate buffer (pH 7.2) for 
one minute. The glass chip was analyzed by a confocal laser 
scanning microscope LSM 510 META (Carl Zeiss, Jena, 
Germany). The signal intensity was determined by software 
for the LSM510 (LSM Image Browser). A histogram of the 
intensity was obtained from the region of the spotted chip. 
The value of the signal intensity was obtained by calculating 
and expressing it as the mean intensity.
Results and discussion
Schematic outline of the biochip
The biochip, a solid-phase assay method to investigate 
protein-RNA interaction, is becoming an attractive tool in 
biotechnology today for diagnostic and therapeutic pur-
poses as well as for basic research. We designed a highly 
sensitive biochip using a ProteoChip coated with ProLinker, 
a novel calixcrown derivative with a bifunctional coupling 
property that permits efficient immobilization of captured 
viral protein on solid matrices and makes a simple analysis 
of protein-RNA interactions possible.33 Specific detection 
of the viral protein was demonstrated by QDs-conjugated 
RNA oligonucleotide on the biochip. The full procedure for 
detection on biochip is as follows. First, the viral protein 
was spotted on a glass chip with carboxyl as the functional 
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Figure 1 Representative scheme for the detection of viral protein on chip.  A) Scheme for viral protein assay on chip. B) Procedure for viral protein assay.International Journal of Nanomedicine 2010:5 326
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group. Second, the QDs-conjugated RNA oligonucleotide 
was bound on an immobilized chip. Third, the bound chip 
was washed to remove nonspecific binding. Fourth, it was 
analyzed to identify the specific detection of viral protein on 
the biochip. The targeting process for effective monitoring 
of the viral protein on the biochip is illustrated in Figure 1. 
Feasibility of targeting and imaging was achieved by using 
QDs525 conjugates containing RNA oligonucleotide for 
specific NS5B viral protein.
QDs-conjugated RNA oligonucleotide
The QDs-supported RNA oligonucleotide was conju-
gated via amide formation from coupling of the 5'-end-
amine-modified RNA oligonucleotide at the surface of QDs 
  displaying carboxyl groups via standard EDC coupling. 
Formation of the QDs-conjugated RNA oligonucleotide 
was confirmed on 2% agarose gel at 100 V in Tris-acetate-
EDTA buffer. Agarose gel electrophoresis showed a 
  distinct mobile band pattern between the free QDs and 
the QDs-conjugated RNA oligonucleotide, confirming 
the formation of QDs-conjugated RNA oligonucleotide. 
The mobility shifts are compared in Figure 2. On agarose 
gel, both the QDs-conjugated NS5Bnor RNA oligonucleotide 
and the NS5Bmut oligonucleotide showed less mobility shift 
than free QDs, thereby demonstrating conjugation by amide 
formation between the QDs and RNA oligonucleotide.
By TEM, both the QDs and the QDs-conjugated RNA 
oligonucleotide appeared spherical and fairly monodispersed 
(Figure 3). In Figure 3A, only the free QDs nanoparticles are 
visible. In addition, the nanoparticles appeared to be evenly 
distributed on the surface. Both the QDs and the RNA oli-
gonucleotide were conjugated in the EDC coupling reaction. 
The QDs (dark spot) was surrounded by a white disk of 
conjugated RNA oligonucleotide (Figure 3B).
Detection of viral protein on biochip
The recombinant HCV NS5B viral protein in the E. coli 
expression system was expressed and purified by Ni-NTA 
affinity chromatography. In the purification step, the protein 
was eluted in 1 mL fractions with 250 mM imidazole buffer. 
To verify the purity and homogeneity of the eluted NS5B, 
aliquots of eluted fractions were analyzed by Coomassie blue 
staining on SDS-PAGE. Eluates with a purity of 95% were 
pooled, dialyzed and stored with 50% glycerol in aliquots at 
-80°C. The HCV NS5B viral protein was purified by a single 
chromatography step on a Ni2+ affinity column. The C-termi-
nally his-tagged HCV NS5B was visualized with a molecular 
mass of approximately 66 kDa on SDS-PAGE (Figure 4).
We demonstrated the specific interaction between QDs-
conjugated RNA oligonucleotide and immobilized HCV 
NS5B viral protein on a chip. As illustrated in Figure 5A, 
the QDs-NS5Bnor RNA oligonucleotide-treated conjugates 
showed high fluorescent signals on the chip. In Figure 5B, 
no fluorescence signal was detected with a NS5Bmut RNA 
oligonucleotide, because of its lack of affinity. The signal of 
QDs-conjugated NS5Bmut RNA oligonucleotide for protein-
binding affinity was very similar to the background signal. 
Figure 5C shows that QDs-conjugated RNA oligonucleotide 
is selective for HCV NS5B viral protein at varying protein 
concentrations. The binding affinity by confocal assay with 
varying concentrations of the NS5B viral protein was exam-
1 2 3
Figure 2 The conjugation pattern on 2% agarose gel electrophoresis was examined at 
UV excitation wavelength (345 nm), free QDs (lane 1), QDs-NS5Bnor RNA oligonucle-
otide (lane 2), and QDs-NS5Bmut RNA oligonucleotide (lane 3). Carboxyl-terminated 
QDs are conjugated with RNA oligonucleotide by an amine-carboxyl reaction.
Abbreviations:  NS5B,  nonstructural  protein  5B;  QDs,  quantum  dots; 
UV, ultraviolet.
A B
Figure 3 Characterization of QDs by  TEM analysis. A) Free QDs. B) QDs-conjugated 
RNA oligonucleotide.
Abbreviations: QDs, quantum dots; TEM, transmission electron microscopy.International Journal of Nanomedicine 2010:5 327
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ined, and it was observed that the signal intensity of the QDs-
conjugated RNA oligonucleotide could be detected even at 
the lowest concentration (1 ng mL-1). The signal intensity 
was found to increase gradually by up to 1ng mL-1 of protein 
concentration. The insert figure in Figure 5D shows that the 
detection limit of this method was at the 1 ng mL-1 level.
These results suggest the NS5B RNA oligonucleotide 
could specifically target the HCV NS5B viral protein on an 
immobilized chip. These results show that the QDs-RNA 
oligonucleotide could be effective for the quantification of 
HCV NS5B viral protein. To confirm a competition reaction 
of specific binding, BSA was used as a negative control 
protein. No fluorescence signal was detected with BSA 
(data not shown). Using the QDs-RNA oligonucleotide, we 
developed a HCV biosensor prototype biochip that could 
detect and quantify the HCV NS5B viral protein. Here, the 
specific RNA oligonucleotide was examined for binding to 
the HCV NS5B viral protein by using a QDs-conjugated 
imaging system. HCV-specific targeting and imaging using 
a QDs-conjugated RNA oligonucleotide agent was dem-
onstrated. Preferential binding of QDs-conjugated RNA 
oligonucleotide for detection of HCV NS5B viral protein was 
determined by analyzing fluorescence intensity measured by 
confocal microscopy. The immobilized protein chip showed 
no binding to NS5Bmut RNA oligonucleotide, thus demon-
strating selectivity for HCV NS5B viral protein. Imaging by 
semiconductor nanocrystal QDs allows for monitoring with 
intense light emission and accuracy.
70
M 1 2 3 M 4
50
Figure 4 Purification of HCV-NS5B viral protein. The SDS-PAGE 10% gel show-
ing NS5B protein with his-tag. M, protein marker; lane 1, before induction form of 
NS5B; lane 2, total form of NS5B; lane 3, soluble form of NS5B; lane 4, his-Tag form 
of NS5B.
Abbreviations: HCV, hepatitis C virus; NS5B, non-structural protein 5B; SDS-PAGE, 
sodium dodecyl sulfate polyacrylamide gel electrophoresis.
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Figure 5 A, B) Selective specificity of HCV-NS5B viral protein by QDs-conjugated RNA oligonucleotide. The NS5Bnor and NS5Bmut RNA oligonucleotides were bound on 
an immobilized viral protein chip, respectively. C, D) Effect of HCV-NS5B viral protein concentrations on binding assay.
Abbreviations: HCV, hepatitis C virus; NS5B, non-structural protein 5B; NS5Bnor, normal NS5B; NS5Bmut, mutant NS5B; QDS, quantum dots.International Journal of Nanomedicine 2010:5 328
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During the last decade, there has been an increasing inter-
est in using nanoparticles in biologic applications. The avail-
ability of colloidal semiconductor QDs with highly controlled 
optical properties in the nanometer size range has created 
widespread interest in the use of biotechnologic systems as 
a diagnostic platform and for biologic imaging. In this study, 
we report a QDs-conjugated RNA oligonucleotide probe for 
screening of HCV with high sensitivity and selectivity.
A RNA oligonucleotide sensor system that could quantify 
HCV NS5B viral protein using conjugated QDs-RNA oligo-
nucleotide could provide an efficient strategy and a promising 
new platform for monitoring applications.
In summary, we have shown that QDs-RNA oligonucle-
otide can specifically recognize the HCV viral protein, and 
have demonstrated that this conjugated QDs-RNA oligo-
nucleotide can interact on a designed biochip specifically and 
sensitively. This device could generate a QDs-conjugated 
biosensor prototype biochip for HCV diagnosis. The present 
visual HCV detection technique may avoid the limitations 
with its reported methods, namely, its high sensitivity, good 
specificity, simplicity, speed, and cost-effectiveness. This 
technique has potential applications in many fields, especially 
in multiple virus detection chip coupled with nanoparticle 
will find applications in clinic.
Conclusions
The results of this study indicate that the QDs-conjugated 
RNA oligonucleotide can recognize the HCV viral protein 
with a detection limit of 1 ng mL-1 specifically and sensi-
tively on a designed biochip. This device could generate 
a nanoparticle-conjugated prototype biochip for HCV 
diagnosis.
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